GS1-05 Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

GS1-04 Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status

GS1-07 Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207

GS1-01 Race and Clinical Outcomes in the RxPONDER Trial (SWOG S1007)

GS1-10 Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2 advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

GS1-11 Sacituzumab Govitecan vs Treatment of Physicians Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients With HR+/HER2 Metastatic Breast Cancer

GS1-06 Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

GS2-01 Trastuzumab deruxtecan vs physician s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

Low HER2- A separate entity? Published Data and SABCS News: a pathologist s perspective

SPOTLIGHT POSTER DISCUSSION SESSION #15 - Hemisfair Ballroom 1&2 Local Regional/Management of the Axilla

GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

GS3-06 PACE: Palbociclib After CDK and Endocrine Theraov A Randomized Phase II Stud of Fulvestrant +/- Palbociclib after Progression on CDK4/6 inhibitor for HR+/HER2- Metastatic Breast Cancer

GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

GS3-09 Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer: overall survival analysis of the randomized STIC CTC trial

GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting

GS3-09 Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer: overall survival analysis of the randomized STIC CTC trial

GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

GS4-02 The OPBC-04/EUBREAST-06/OMA Study: Oncological Outcomes Following Sentinel Lymph Node Biopsy (SLNB) or Targeted Axillary Dissection (TAD) in Breast Cancer Patients Downstaging From Node Positive To Node Negative with Neoadjuvant Chemotherapy

GS4-08 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer

GS4-09 Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13 / Alliance A221405)

GS4-01 Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer - Results from ACOSOG Z11102 (Alliance)

GS4-03 Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy

GS4-05 Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy

GS4-08 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer

GS4-04 Population-based Estimates of contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

GS4-02 The OPBC-04/EUBREAST-06/OMA Study: Oncological Outcomes Following Sentinel Lymph Node Biopsy (SLNB) or Targeted Axillary Dissection (TAD) in Breast Cancer Patients Downstaging From Node Positive To Node Negative with Neoadjuvant Chemotherapy

GS5-04 Identification of symptoms that are associated with irAEs in the I-SPY trial

GS5-02 Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

GS5-01 Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial

GS5-03 Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

YIR-01 Basic science

YIR-02 Translational Breast Cancer Research

YIR-03 Early Breast Cancer

YIR-04 Advanced Breast Cancer